glp-1 and substance use disorder Receptor Agonists Research to Treat Overeating and Disorders The Growing Scientific Case for

SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) such as empagliflozin, dapagliflozin, and canagliflozin represent excellent alternatives, providing cardiovascular and renal protection alongside modest weight loss (typically 2-4 kg)

Quick Answer: GLP-1-related bloating can be reduced through smaller frequent meals, avoiding high-fat and gas-producing foods, eating slowly, gentle post-meal walking, and dose adjustment strategies under medical supervision

Constipation in DM are associated with both poor glycemic control and diabetic complications: current status and future directions

Limit processed foods high in added sugars, unhealthy fats, and sodium to maintain stable blood sugar levels

Defining the Sensation: Dizziness vs

This article compares those pathways using FDA and manufacturer disclosures and platform terms as of December 26, 2025